MP-0250

N/A

Report date: 2026/01/13 20:00:24

Base Information

Drug NameMP-0250
Drug Alias NameDesigned repeat proteins research programmeDPR research programmeMP-0250
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionHepatocyte growth factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor AHepatocyte growth factor
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungMultiple MyelomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMolecular Partners Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMolecular Partners Ag
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungMultiple MyelomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A